Literature DB >> 23216526

Risk factors for mixed complicated skin and skin structure infections to help tailor appropriate empiric therapy.

Marya Zilberberg1, Scott T Micek, Marin H Kollef, Ahmed Shelbaya, Andrew F Shorr.   

Abstract

BACKGROUND: Complicated skin and skin structure infections (cSSSIs) are a common reason for hospitalization. Inappropriate empiric therapy prolongs the hospital stay. Strategies that help clinicians target empiric therapy underlie antibiotic stewardship. We developed an algorithm to identify mixed (gram-positive+gram-negative organisms) cSSSI at hospital admission.
METHODS: We performed a retrospective cohort study at a single academic medical center among patients hospitalized from April 2006 to December 2007 with a cSSSI. Inappropriate empiric therapy was defined as failure to deliver an antibiotic with in vitro activity against the offending pathogen(s) within 24 h of presentation. We derived a predictive rule to identify patients at risk for a mixed skin infection (MSI) and compared it with the "healthcare-associated" (HCA) definition.
RESULTS: Among 717 patients hospitalized with a cSSSI, 68 (9.5%) had an MSI, with 38.2% of these receiving inappropriate empiric therapy. Intensive care unit admission (odds ratio [OR] 2.49; 95% confidence interval [CI] 1.12-5.52), infection other than an abscess (OR 2.01; 95% CI 1.06-3.81), and nursing home residence (OR 1.99; 95% CI 1.05-3.78) predicted MSI independently. The absence of all three factors identified non-MSI with 95.2% accuracy. The MSI rule improved the HCA classification accuracy for non-MSI by 21.9% without any loss in sensitivity.
CONCLUSIONS: Hospitalization with an MSI is a risk factor for inappropriate empiric therapy. Intensive care unit admission, infection other than an abscess, and nursing home residence help identify those patients with a higher MSI risk. Absence of all these factors reliably identified patients not needing empiric MSI coverage. Relative to the HCA definition, the MSI rule resulted in the potential to prevent more than one in five additional patients from receiving unnecessarily broad empiric coverage.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23216526     DOI: 10.1089/sur.2011.101

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  5 in total

Review 1.  Diagnosis and management of skin and soft tissue infections in the intensive care unit: a review.

Authors:  Jason P Burnham; John P Kirby; Marin H Kollef
Journal:  Intensive Care Med       Date:  2016-10-03       Impact factor: 17.440

Review 2.  Current Epidemiology, Etiology, and Burden of Acute Skin Infections in the United States.

Authors:  Keith S Kaye; Lindsay A Petty; Andrew F Shorr; Marya D Zilberberg
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

3.  Update on the epidemiology of healthcare-acquired bacterial infections: focus on complicated skin and skin structure infections.

Authors:  Mark H Wilcox; Matthew Dryden
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

4.  Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.

Authors:  J Pullman; J Gardovskis; B Farley; E Sun; M Quintas; L Lawrence; R Ling; S Cammarata
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

5.  Management of hospital-acquired infections among patients hospitalized at Zewditu memorial hospital, Addis Ababa, Ethiopia: A prospective cross-sectional study.

Authors:  Segen Gebremeskel Tassew; Minyahil Alebachew Woldu; Wondwossen Amogne Degu; Workineh Shibeshi
Journal:  PLoS One       Date:  2020-04-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.